Genomics USA

Name

Genomics USA

Legal name

GMSbiotech, Inc.

Website

https://gmsbiotech.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Clinical Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industries

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• HLA typing diagnostics
• Microarray diagnostic kits
• Transplantation testing products
• Blood antigen genotyping
• Molecular diagnostic chips

Headquarters

HQ city

Tucson

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Diagnostic Products: Sales of FDA-approved microarray-based diagnostic products including HLA typing tests, antibody screening assays, and blood genotyping chips
2. Technology Licensing: Non-exclusive licensing of DNA microarray and sample amplification technologies for various fields; exclusive licensing of protein microarray for HLA diagnostics. Revenue includes up-front payments, minimum royalty payments, and R&D contracts
3. Government Grants: SBIR funding from NIH institutes including NIAID, NHLBI for development of sHLA Chip, Transfusion Chip, and HLA typing technology
4. Companion Software: Ricimer software sold as companion product to molecular typing and antibody screening products

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Genomics USA (d/b/a GMSbiotech, Inc.) develops and fabricates microarray-based diagnostic kits for DNA and protein analysis, with a focus on transplantation and transfusion medicine. Its flagship products include the EZMatch HLA typing test, EZScreen donor specific antibody detection assay, the Transfusion Chip (T-Chip) for blood antigen genotyping, and the Ricimer companion analysis software, all powered by its proprietary Raw Sample Genotyping (RSG) technology that bypasses DNA purification.

Product overview

GMSbiotech operates a platform-plus-products model centered on the GMSbio-Chip microarray technology. The core platform enables direct genotyping from raw samples (blood, cheek swabs, dried blood spots) without DNA purification, cutting workflow time and cost by approximately 50%. The commercial product portfolio includes EZMatch™ for HLA tissue typing in transplantation, EZScreen™ for Donor Specific Antibody detection in transplant recipients, Ricimer™ companion analysis software, and the Transfusion Chip (T-Chip) for blood antigen genotyping. All products leverage the same underlying microarray platform technology and Raw Sample Genotyping (RSG) methodology.

Differentiator

Problem solved

Functional benefit

Brands

• EZMatch™: HLA typing test for the transplantation market based on Human Leukocyte Antigen (HLA) typing.
• EZScreen™
• Ricimer™
• Transfusion Chip
• GMSbio-Chip
• sHLA Chip

Products and services

• EZMatch Test

Quantifiable outcome

• 50% reduction in cost per test compared to traditional genotyping methods
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Pure Protein LLCcoreStrategic or Co-development Partner · 5 April 2016Joint venture established in 2016 to develop sHLA chip for Anti HLA Antibody Screening & Monitoring. GMSbiotech provides its proprietary protein array platform while Pure Protein contributes its patented sHLA proteins. Collaboration expanded with $3M SBIR Phase IIB grant from NIAID in February 2018.
• Pathogen DxminorOEM/ Whitelabel/ Licensing Partner · 1 August 2015Exclusive out-licensing of Raw Sample Genotyping (RSG) Technology for agricultural testing applications. Agreement includes up-front payments, minimum royalty payments, and R&D contracts to GMSbiotech.
• Pure Transplant Solutions (PTS) LLCcoreStrategic or Co-development PartnerCollaboration for development of EZScreen Donor Specific Antibody screening and monitoring test product line. EZScreen will feature HLA Class I & II native antibody detection for pre- and post-transplantation testing.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Agilent Technologies: Agilent provides microarray and molecular diagnostic technologies used in clinical research. Competes with GMSbiotech's GMSbio-Chip platform in the broader microarray and genomics instrumentation market.
• Illumina: Illumina's NGS sequencing platforms (MiSeq, NextSeq, iSeq) have become the dominant technology for high-resolution HLA typing in clinical labs. While not a direct microarray competitor, Illumina's installed base and continued technology investment have displaced microarray-based approaches in many HLA workflows.
• DiaSorin (Luminex): DiaSorin acquired Luminex in 2021 to expand its multiplex diagnostics franchise. Luminex's xMAP bead-based multiplex platform competes with GMSbiotech's microarray technology in the high-throughput clinical diagnostics market.
• Bio-Rad Laboratories: Bio-Rad Laboratories offers molecular diagnostics products including HLA typing kits and the Bio-Plex multiplex assay platform. As a larger incumbent diagnostics player, Bio-Rad competes across multiple molecular testing modalities relevant to GMSbiotech's transplant and transfusion testing markets.
• CareDx: CareDx is a transplant diagnostics company offering AlloSure (donor-derived cell-free DNA testing) for transplant rejection surveillance. While focused on different methodologies (cfDNA), CareDx addresses the same transplant monitoring clinical use case as GMSbiotech's products.

Direct peers

• GenDx: GenDx is a specialized HLA typing company offering both Sanger sequencing and NGS-based HLA typing kits and software. Directly competes with EZMatch in clinical HLA typing and serves the same transplant laboratory customer base.
• Quotient: Quotient provides molecular immunohematology products including the MosaiQ platform for blood typing and disease screening. Directly competes with GMSbiotech's Transfusion Chip in the molecular blood typing and transfusion diagnostics market.
• Immucor: Immucor is a leading provider of transfusion and transplantation diagnostics including blood bank reagents and molecular blood typing. Directly competes with GMSbiotech's Transfusion Chip in the blood antigen genotyping market serving blood banks and transfusion services.
• One Lambda (Thermo Fisher Scientific): One Lambda, acquired by Thermo Fisher in 2012, is the dominant commercial provider of HLA typing reagents and antibody detection assays for transplantation medicine. Directly competes with GMSbiotech's EZMatch and EZScreen products in the same target market of histocompatibility laboratories.

Emerging players

• Pathogen Dx: Pathogen Dx is the licensee of GMSbiotech's Raw Sample Genotyping (RSG) technology for agricultural testing applications. While not a direct competitor, this technology partnership makes Pathogen Dx a relevant comparable in the genomics testing space with overlapping R&D and customer development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genomics-usa

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomics USA